IMT504 is a novel oligodeoxynucleotide immunotherapy that has shown robust results in numerous animal safety and efficacy models, as well as in humans. Recent data suggest that IMT504 will be a highly effective therapy for addressing Rabies and COVID-19. Additional exciting data suggests that the IMT504 platform could be an effective treatment for other diseases too.
IMT504 is our proprietary, patented technology platform with over $23 Million invested in research. Our technology platform creates a very rapid, safe and effective immune system response. IMT504 has the ability to address emergency situations like the current COVID-19 pandemic.